Ir para o conteúdo principal

ProPhase Labs (NYSE: PRPH) — Perfil da empresa, notícias e dados financeiros

Logo de ProPhase Labs
PRPH ProPhase Labs
ProPhase Labs primary media
Perfil da empresa

ProPhase Labs

ProPhase Labs (NASDAQ:PRPH) is a diversified medical science and technology company with a focus on developing innovative solutions across diagnostics, genomics, and biotechnology spaces. The company is committed to leveraging its expertise in molecular biology to create advancements in disease detection and analysis, aiming to improve patient outcomes and healthcare efficiency. Projects under ProPhase Labs' umbrella include the development of advanced diagnostic tests for infectious diseases and genomic testing services that provide critical insights for personalized medicine. Objectives for the company revolve around expanding its market presence through cutting-edge research, strategic partnerships, and the acquisition of complementary technologies to address pressing health challenges.

Resumo

Public USParticipação acionária
1989Ano de fundação
129Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de ProPhase Labs

  • DNA testing services tailored for individual genetic markers ensuring personalized healthcare and wellness insights.
  • Rapid test kits for COVID-19, providing quick and reliable detection of the virus.
  • Over-the-counter cold remedy formulation designed to reduce symptom severity and duration.
  • Genetic testing kits for consumer use, offering insights into ancestry, traits, and health predispositions.
  • Immune support supplements, leveraging scientific research to boost the body's natural defenses.
  • Contract manufacturing services, offering comprehensive solutions from product development to market readiness for healthcare products.

equipe executiva do ProPhase Labs

  • Mr. Ted William KarkusChairman & CEO
  • Mr. Jason KarkusPresident of Nebula Genomics
  • Mr. Kevin QuinnChief Product Officer of Nebula Genomics

Histórico de dividendos

Dividendos por ação pagos pela ProPhase Labs, por ano fiscal.

Dividendos por ação da ProPhase Labs por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2021—$6.0000—$6.0000
FY2020—$3.0000—$3.0000
FY2019$2.5000——$2.5000
FY2018—$2.5000—$2.5000
FY2017—$20.0000—$20.0000

Principais indicadores financeiros

Resultados divulgados pela ProPhase Labs, em USD.

Receita e lucro anuais da ProPhase Labs
Fim do ano fiscalReceitaResultado operacionalLucro líquido
4,3 mi-18 mi-14,7 mi
6,8 mi-38,6 mi-53,4 mi
44,4 mi-21,6 mi-16,8 mi
122,6 mi23,6 mi18,5 mi